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Abstract
Background: The phosphatidylinositol-3-kinase (PI3K-PKB), mitogen activated protein kinase (MEK-ERK) and the
mammalian target of rapamycin (mTOR- p70S6K), are thought to regulate many aspects of tumour cell proliferation
and survival. We have examined the utilisation of these three signalling pathways in a number of cell lines derived
from patients with metastatic malignant melanoma of known PIK3CA, PTEN, NRAS and BRAF mutational status.
Methods: Western blotting was used to compare the phosphorylation status of components of the PI3K-PKB, MEK-
ERK and mTOR-p70S6K signalling pathways, as indices of pathway utilisation.
Results: Normal melanocytes could not be distinguished from melanoma cells on the basis of pathway utilisation
when grown in the presence of serum, but could be distinguished upon serum starvation, where signalling protein
phosphorylation was generally abrogated. Surprisingly, the differential utilisation of individual pathways was not
consistently associated with the presence of an oncogenic or tumour suppressor mutation of genes in these
pathways.
Conclusion: Utilisation of the PI3K-PKB, MEK-ERK and mTOR-p70S6K signalling pathways in melanoma, as
determined by phosphorylation of signalling components, varies widely across a series of cell lines, and does not
directly reflect mutation of genes coding these components. The main difference between cultured normal
melanocytes and melanoma cells is not the pathway utilisation itself, but rather in the serum dependence of
pathway utilisation.
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Background
Melanocytes are specialised cells found predominantly
in the dermis, hair follicles and eyes, where they have a
number of functions including the production of mela-
nin [1] and of other factors including cytokines that act
on peripheral cells [2]. Melanomas are thought to arise
from excessive proliferation of melanocyte precursors.
Melanoma is the most aggressive form of skin cancer
that is largely refractory to radiotherapy and cytotoxic
drugs and the rapidity of appearance of metastatic
lesions also compromises the efficacy of surgery [3].
Growth factor signalling pathways play a key role in
relaying extracellular signals from growth factor binding
to receptor tyrosine kinases on the plasma membrane to
the nucleus via a cascade of phosphorylation events to
regulate diverse processes such as proliferation, differen-
tiation, survival and migration in normal melanocytes
[4]. The mitogen activated protein kinase (MAPK) sig-
nalling cascade is comprised of three-tier kinases that
are activated when phosphorylated. The extracellular
signal regulated kinase (ERK) pathway is the most stu-
died of the mammalian MAPK pathways and is fre-
quently deregulated in many cancers. ERK1 and ERK2
are activated upon phosphorylation by MEK, which is
itself activated when phosphorylated by Raf [5]. The
phosphatidylinositol 3-kinase (PI3K) pathway is a second
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any medium, provided the original work is properly cited.important intracellular signalling pathway and generates
phosphatidylinositol-3,4,5-triphosphate (PIP3), a second
messenger which induces downstream phosphorylation
and activation of protein kinase B (PKB also known as
Akt). The generation of the second messenger PIP3 is
antagonised by the tumour suppressor phosphatase and
tensin homologue (PTEN) [6]. The mammalian target of
rapamycin (mTOR) is a multidomain protein that is
related to the PI3K enzymes and mediates signalling to
regulate cellular growth and size [7]. Both PI3K and
MAPK pathways crosstalk extensively with the mTOR
pathway to mediate different cellular functions through
two different proteins, ribosomal protein S6 kinase
(S6K) and 4E-binding protein (4EBP) [8].
A large fraction of melanomas harbour activating
oncogenic or inactivating tumour suppressor gene muta-
tions in the growth factor signalling pathways. Muta-
tions in BRAF occur in 40%-60% of melanomas [9,10]
and 15%-30% of melanomas harbour activating NRAS
mutations [10,11]. It is notable that a large percentage
of BRAF mutant melanomas also contain deletions or
mutations in the PTEN gene [11]. Although activating
mutations of the p110 alpha isoform of PI3K (PIK3CA)
also contribute to tumourigenesis in many types of can-
cer [12], they are found only at a low frequency in mela-
noma [13,14]. However, the activation of the PI3K
pathway is more commonly associated with melanoma.
In BRAF mutant cells, loss of PTEN function plays an
important role in the development of melanoma in
mouse models, as BRAF mutations alone do not induce
melanoma but melanoma develops when PTEN is
deleted in melanocytes which harbour the BRAF muta-
tion [15-17]. Current evidence indicates that the PI3K
pathway play an important role in melanomas as inhibi-
tors of the PI3K pathway synergise with inhibitors of
the MAPK pathway in inhibiting the proliferation of
many melanomas [18-20].
The discovery that most human melanomas harbour
mutations in either BRAF or NRAS has led to the devel-
opment of targeted therapies, such as inhibitors of MEK
or BRAF [21]. BRAF inhibitors have been developed
that have quite dramatic effects on patients with mutant
BRAF tumours [22,23]. However responses are followed
by the development of resistance [23,24]. Recent studies
have outlined the mechanisms whereby melanoma cells
acquire resistance by bypassing the signalling pathway
that is targeted by the drug. Thus there is a need to
understand which signalling pathways are activated in
melanoma and how these differ from those used by nor-
mal, benign melanocytes.
In an effort to provide a better understanding of the
signalling pathways of normal and malignant melano-
cytes cells, we have cultured samples of surgically
resected metastatic melanomas [25] and established over
one hundred early passage melanoma cell lines [26-28].
We have analysed these cell lines at early passage for
loss of PTEN and for mutations in BRAF, NRAS and
PIK3CA and have chosen a subset that is representative
of the main patterns of mutation. We have analysed the
main signalling pathways of these cell lines and com-
pared them to those of a cell line derived from normal
melanocytes. We have characterised the expression and
phosphorylation status of the main components of the
PI3K and MAPK pathways by western blotting and
compared this to gene mutation data. Surprisingly we
have found that the pattern of pathway utilisation in
normal melanocytes was not distinct from those exhib-
i t e db yt h em e l a n o m al i n e si nt h ep r e s e n c eo fs e r u m .
However differences become evident in the absence of
serum. Thus, we show that early passage metastatic mel-
anoma cell lines have deregulated growth factor signal-
ling pathways in comparison to primary melanocytes,
but that this phenomenon is most clearly manifested
upon serum withdrawal.
Methods
Culture of melanoma cells and melanocytes
The 12 New Zealand melanoma (NZM) cell lines used
for this study were generated from metastatic melanoma
after written consent was obtained from all patients
under Auckland Area Health Board Ethics Committee
guidelines as previously described [27]. NZM cell lines
were grown under low oxygen conditions (5% O2)i n
order to mimic physiologically low oxygen levels in
tumours. NZM lines were grown in a minimal essential
medium (aMEM) (Invitrogen, USA) supplemented with
insulin (5 μg/mL), transferrin (5 μg/mL) and sodium
selenite (5 ng/mL) (Roche Applied Sciences, Germany),
100 units/mL of penicillin, 100 μg/mL of streptomycin
(PS) and 5% fetal bovine serum (FBS). In order to starve
cells of serum, culture plates were washed with PBS and
incubated with serum free medium (aMEM without
FBS and ITS supplement) for 16 hours. Human melano-
cytes were purchased from Invitrogen and grown in
light sensitive Medium 254 supplemented with human
melanocyte growth supplement (HMGS-2) (Invitrogen)
and PS. Human melanocytes were cultured in an atmo-
sphere of 5% CO2 in air at 37°C.
Genetic analyses of PIK3CA, PTEN, NRAS and BRAF in
NZM cell lines
Melanoma cell lines were sequenced for hotspot muta-
tions in BRAF exons 11 and 15 and NRAS exons 1 and
2. The entire coding region of PTEN was also
sequenced. The PCR primers for BRAF exon 11 were
from a published source [9] and the full list of PCR pri-
mer sequences are shown in Additional file 1. The PCR
reactions were conducted using Taq polymerase,
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Taq polymerase [29].
BRAF, NRAS and PTEN sequencing reactions were
conducted using the PCR primers and sequencing pri-
mers that were designed to bind to the PCR product,
and run using thermal cycle sequencing with Big Dye
Terminator 3.1 chemistry (Applied Biosystems, USA).
The reactions were run on a 3130XL Applied Biosys-
tems capillary sequencer (DNA Sequencing Facility,
University of Auckland). Mutations were detected
manually, using the Codon Code aligner 2.0 programme
(CodonCode Corporation), and confirmed by repetition
of sequencing from separately amplified material.
Screening for mutations was done in all exons of the
PIK3CA gene by PCR-single-strand conformational poly-
morphism (SSCP) as outlined in Campbell et al. [30] at
the Peter MacCallum Cancer Institute in Melbourne,
Australia. Mutations were confirmed by sequencing in
both directions.
Western blotting
After NZM cells were grown to about 80% confluence
in the presence of serum or serum starved for 16 hours,
they were washed in ice-cold PBS, lysed in radioimmu-
noprecipitation assay (RIPA) buffer and prepared for
western blotting as previously described [31]. Antibodies
used were specific for the following epitopes: phos-
phorylated PKB at Ser473 and Thr308, phosphorylated
p70S6K at Thr389, phosphorylated ribosomal protein S6
at Ser240/244 and 235/236, phosphorylated MEK1/2 at
Ser217/221 and phosphorylated ERK1/2 at Thr202/
Tyr204. Antibodies recognising total PTEN, PKB,
p70S6K, rpS6, MEK1/2 and ERK1/2 were also used. All
of the above antibodies were from Cell Signaling Tech-
nology (USA). b-actin antibody was from Sigma.
Results
NZM cell line mutations in the PI3K and MAPK pathways
In order to determine whether the presence of activating
mutations in the PI3K and MAPK signalling pathways
correlated with increased utilisation of downstream sig-
nalling pathways, we first determined the mutational
status of PIK3CA, PTEN, NRAS and BRAF genes in the
NZM cell line collection. Representative DNA sequences
for PTEN, PIK3CA, BRAF and NRAS are provided in
Figure 1. As shown in Table 1, we selected cell lines
that were characterised by a number of genetic muta-
tions. All of the selected cell lines harboured either
oncogenic V600E or V600K BRAF or Q61H NRAS
mutations. Since the tumour suppressor gene PTEN can
be functionally lost during melanoma development
through both mutation and epigenetic mechanisms [32],
we measured PTEN protein expression in the NZM cell
lines (Figure 2). Mutation of the PTEN gene led to loss
of functional PTEN protein expression, as seen in Figure
2. The cell lines NZM40, NZM46 and NZM52, which
all harbour the oncogenic H1047R PIK3CA mutation,
had concurrent BRAF or NRAS mutations (Table 1). Of
particular interest was the high degree of expression of
PTEN protein in the NZM46 cell line, compared to
other cell lines harbouring the PIK3CA oncogenic muta-
tion. Since the presence of an oncogenic mutation or a
loss of tumour suppressor function does not dictate
whether the cell uses all of the downstream signalling
molecules for pathway activation [33,34], we determined
the phosphorylation status of the immediate down-
stream substrates of the PI3K, mTOR and MAPK path-
ways. Western blots for phosphorylated molecules were
used as surrogate markers for pathway activation.
Phosphorylation of PKB in melanoma and melanocytes
In order to establish whether PIK3CA, PTEN, NRAS and
BRAF mutations resulted in constitutive activation of
the downstream signalling pathways, we measured PKB
activation by western blotting for phosphorylation at
two sites, Ser473 and Thr308. Equal amounts of protein
from NZM cell lines were loaded onto the same gel, but
for clarity, western blots were segmented to show results
for individual NZM cell lines. In melanocytes, phosphor-
ylation of PKB on both Ser473 and Thr308 was strongly
serum dependent while most of the NZM cell lines in
this study showed serum independent phosphorylation.
PKB was phosphorylated independently of serum at the
mTORC2 dependent Ser473 site in most of the cell
lines, although NZM46 and NZM3 surprisingly had very
low levels of phosphorylation even in the presence of
serum (Figure 3). In contrast, phosphorylation at the
PIP3-PDK1 dependent Thr308 site tended to be low in
the serum starved state in most cell lines and increased
with serum (Figure 3). The notable exceptions were cell
lines NZM12, NZM40 and NZM52 which have com-
paratively high Thr308 phosphorylation in serum
starved cells. Phosphorylation of Thr308 in the NZM40
and NZM52 cell lines may be explained by the activat-
ing PIK3CA mutation in these cells. These two cell lines
also have a very low level of total PKB suggesting some
feedback regulation of PKB gene expression in these
cells. In support of this, NZM46, which also has a
PIK3CA mutation (Figure 3), also has very high PTEN
levels (Figure 2) which could explain the low Thr308
phosphorylation in these cells and the higher levels of
total PKB compared to NZM40 and NZM52, as PIP3
levels would be predicted to be low despite the PIK3CA
mutation. NZM46 shows suppression of phosphoryla-
tion by serum in the Thr308 site (as with the Ser473
site).
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melanoma cells and melanocytes
Activation of components of the protein translation
machinery has been observed in a large percentage of
melanomas and is predictive of a poor prognosis [35].
The PI3K signalling pathway can regulate protein trans-
lation machinery through mTORC1 and subsequent
activation of p70S6K and phosphorylation of ribosomal
protein S6 (rpS6). Therefore we next determined the
phosphorylation status of p70S6K (Figure 4). The
p70S6K was strongly expressed in all cell lines as well as
in normal melanocytes but the pattern of phosphoryla-
tion of p70S6K and p85S6K at Thr389 did not correlate
with the phosphorylation status of PKB nor did it corre-
late with genotypes (Figure 4). In melanocytes, the
observed phosphorylation of Ser235/236 was serum
dependent while Ser240/244 site, which is phosphory-
lated by p70S6K, was phosphorylated even in the
absence of serum. In most of the cell lines, we observed
serum independent phosphorylation of rpS6 while in
NZM43 and to some degree, NZM10 and NZM15
showed serum dependent phosphorylation. Interestingly,
we observed little phosphorylation of rpS6 at both sites
in BRAF mutant cell lines, NZM3 and NZM12 (Figure
5). Thus, phosphorylation of rpS6 is independent of
PI3K pathway activation in these melanoma cell lines. In
these cells the phosphorylation of rpS6 is likely due to
input from the ERK signalling cascade as can be seen in
other cell types [36].
Phosphorylation of components of the ERK pathway in
melanoma cells and melanocytes
We also analysed the activation status of the MAPK
pathway in NZM cell lines with NRAS or BRAF muta-
tions and cell lines which additionally harbour PTEN or
PIK3CA mutations. The activation of MEK and then
ERK in response to oncogenic NRAS and BRAF muta-
tions is proposed to be the basis of a MAPK pathway
Figure 1 Examples of sequence electropherograms for wild type (WT) and mutant PTEN, PIK3CA, NRAS and BRAF genes in selected
NZM cell lines. Black arrows on PTEN electropherogram represent the nucleotide deletion resulting in frameshift of the PTEN transcript.
Nucleotide substitutions in PIK3CA, NRAS and BRAF are shown in brackets.
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abundantly expressed in all NZM cell lines as well as
melanocytes (Figure 6). However levels of MEK phos-
phorylation varied considerably and were not directly
related to genotype (Figure 6). Furthermore, NRAS-only
mutant NZM cell lines, NZM10, NZM15 and NZM42
showed very low levels of MEK phosphorylation (Figure
6). ERK was constitutively phosphorylated in almost all
cell lines, and unlike melanocytes, NZM cell lines
showed serum independent MEK and ERK phosphoryla-
tion patterns (Figures 6 and 7). Furthermore, MEK
phosphorylation status did not correlate with ERK phos-
phorylation patterns.
Discussion
Traditionally, signal transduction has been described in
terms of schematic linear pathways in which stimuli
activate or inhibit a series of molecular events that leads
to a predictable series of responses. However, recent
findings have suggested that signalling occurs in a com-
plex network with extensive cross-talk and context-
dependent variations. Signalling pathways also change in
response to abnormal proteins arising from mutations
and from loss of proteins as a result of epigenetic silen-
cing. Cancer cells are thought to have multiple genetic
and epigenetic aberrations, which have complex effects
on the circuitry of these signalling networks. Here, in
melanocytes and in melanoma cell lines, we have stu-
died the phosphorylation status of key PKB, mTOR and
MAPK pathway components downstream of PTEN,
PIK3CA, NRAS and BRAF mutations to determine
whether the activity of the signalling pathways correlates
with the upstream mutation. In melanocytes, phosphor-
ylation patterns conformed to those expected of the
canonical kinase-substrate relationships. Notably, mela-
nocytes showed a consistent serum-dependent phos-
phorylation status of growth factor signalling pathway
proteins. However consistent pattern of phosphorylation
was not seen in melanoma cell lines (Figure 8). Our stu-
dies are in line with recent findings which indicate that
in neoplastic cells, the activity of signalling pathways
does not always correlate with the mutational status of
upstream proteins especially in the MAPK pathway [34].
This heterogeneity in signalling phenotype is consistent
with the high degree of variability in the patterns of
gene expression observed in these melanoma cell lines
[38,39].
Previous studies have shown that PIK3CA mutations
can lead to hyperactivated PI3K signalling pathways
[40]. However, this phenomenon was not consistently
observed in all NZM cell lines studied (Figure 3). Our
results are similar to that of Morrows et al., [41] who
observed different patterns of signalling in colon tumour
cell lines harbouring the same mutation. They are also
consistent with studies by other groups in a range of
non-melanoma cell lines [33,42,43]. A degree of com-
plexity is provided by the results of a recent study of
MCF-7 cells [43], in which all of the sublines developed
from the parental MCF-7 cell line were all expected to
have the same PIK3CA mutation, but not all of the sub-
lines showed strong PKB phosphorylation. The results
suggest that to some extent the signalling phenotype
can be independent of genotype.
All NRAS-only mutant cell lines showed serum-inde-
pendent phosphorylation of ERK1/2 despite no observa-
ble phosphorylation of MEK1/2 (Figure 7). The results
are surprising but are consistent with the observation of
Pratilas et al. [44], who found that ERK phosphorylation
was not indicative of signalling through the MEK path-
way, as ERK phosphorylation is also regulated by nega-
tive feedback loops. Furthermore, ERK1/2 is
Table 1 Mutational status of PIK3CA, PTEN, NRAS and
BRAF genes in New Zealand Melanoma (NZM) cell lines
used for the study
Cell
lines
PTEN status PIK3CA
status
NRAS
status
BRAF
status
NZM6 Exon3 deletion V600E
NZM34 Exon 5
frameshift
mutation
V600E
NZM43 Exon 1
frameshift
mutation
V600K
NZM30 No identified
mutation in
exon
2-9*
V600E
NZM40 H1047R Q61H
NZM46 H1047R Q61H
NZM52 H1047R V600E
NZM10 Q61H
NZM15 Q61H
NZM42 Q61H
NZM3 V600E
NZM12 V600E
*In NZM30, PTEN exon 1 sequencing failed after multiple attempts. The
absence of PTEN protein in NZM30 (Figure 2) could be due to a large deletion
in exon 1 or epigenetic changes
Figure 2 PTEN protein expression in NZM cell lines.E q u a l
amounts of protein in whole cell lysates from NZM cell lines were
immunoblotted for total PTEN protein expression. b-actin is shown
as loading control.
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some NZM cell lines, suggesting MEK independent reg-
ulation of ERK. It has been suggested that PI3K and
classical protein kinase C (cPKC) play a major role in
the MEK-independent prolonged activation of ERK in
some cell types [45,46]. As all the NZM cell lines used
in this study are mutant for either BRAF or NRAS,t h i s
suggests that these oncogenic mutations confer activa-
tion of the MAPK pathway. However, the dominant sig-
nalling pattern observed in all of the NZM cell lines is
serum independent phosphorylation of ERK1/2 com-
p a r e dt om e l a n o c y t e s .W ea l s od i dn o to b s e r v eN Z M
cell lines lacking PTEN function to be strongly asso-
ciated with inactivation of MEK1/2 and ERK1/2 in the
MAPK pathway as noted by Dan et al. (2010) [47]. A
possible explanation for this is that all of the NZM cell
lines studied for functional PTEN loss also have BRAF
mutations. Although Dan et al. [47] suggests that muta-
tions in either NRAS or BRAF a r es t r o n g l yc o r r e l a t e d
with PI3K-PKB pathway inactivation, we did not observe
this in the panel of NZM cell lines.
A further result of this study is that, in the presence of
serum, the phosphorylation pattern of normal melanocytes
is generally similar to that of melanoma cells; differences
are more clearly seen when the cell lines are grown in the
absence of serum. Unlike melanocytes, melanoma cells are
frequently serum independent, may show low phosphory-
lation in the presence of serum and may show suppression
Figure 3 Phosphorylation of PKB on Ser473 and Thr308 in normal melanocytes and NZM cell lines. Western blots representative of three
independent experiments. Western blots are separated into boxes representing each NZM cell line for clarity. Cells were grown in the absence
of FBS for 16 hours (SS) or in the presence of FBS (Ser).
Figure 4 Phosphorylation of p70S6K and p85S6K on Thr389 in normal melanocytes and NZM cell lines. The higher molecular weight
p85S6K and lower molecular weight p70S6K is indicated by arrows. Western blots representative of three independent experiments. Western
blots are separated into boxes representing each NZM cell line for clarity. Cells were grown in the absence of FBS for 16 hours (SS) or in the
presence of FBS (Ser).
Figure 5 Phosphorylation of ribosomal protein S6 (rpS6) on Ser240/244 and Ser235/236 in normal melanocytes and NZM cell lines.
Western blots representative of three independent experiments. Western blots are separated into boxes representing each NZM cell line for
clarity. Cells were grown in the absence of FBS for 16 hours (SS) or in the presence of FBS (Ser).
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argued that the addition of serum, by stimulating multiple
signalling pathways linked to growth factor receptors on
the plasma membrane, obscures the signalling pattern
derived from an activated component such as PI3K or
BRAF, but the data from serum-starved cultures did not
provide any clear relationship between mutational status
and pathway utilisation. Further experiments with specific
inhibitors of these pathways, such as PI3K, PKB, MEK and
mTOR prevented phosphorylation of the corresponding
Figure 6 Phosphorylation of MEK1/2 on Ser217/211 in normal melanocytes and NZM cell lines. Western blots representative of three
independent experiments. Western blots are separated into boxes representing each NZM cell line for clarity. Cells were grown in the absence
of FBS for 16 hours (SS) or in the presence of FBS (Ser).
Figure 7 Phosphorylation of ERK1/2 on Thr202/Tyr204 in normal melanocytes and NZM cell lines. Western blots representative of three
independent experiments. Western blots are separated into boxes representing each NZM cell line for clarity. Cells were grown in the absence
of FBS for 16 hours (SS) or in the presence of FBS (Ser).
Figure 8 Summary of Western blotting results in Figures 3, 4, 5, 6 and 7. Left- and right-hand circles in each cell of the table represent
results for cells grown in the absence (SS) and presence (Ser) of FBS.
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actions of inhibitors does not depend on activation of
upstream signalling molecules. The difference in the
dependence of melanocytes and melanoma cells on serum
growth factors for phosphorylation of downstream signal-
ling molecules could be due to autocrine growth factors
produced in melanomas. It has been noted that melano-
mas produce vascular endothelial growth factor (VEGF)
[48,49] and fibroblast growth factor (FGF) [50], which
could explain this loss of serum dependence. Melanomas
may also over-express growth factor receptors such as
insulin-like growth factor 1 receptor (IGF1-R) [51] and
Axl [52] which can support constitutive activation of some
components of the growth factor pathway.
Conclusion
In conclusion, we found that activation of the growth
factor signalling pathways varied considerably among
a series of NZM cell lines, and that no consistent
relationship was observed between pathway activation,
as measured by protein phosphorylation. However
despite this heterogeneity, there was clearly an obser-
vable difference between melanoma cells and normal
melanocytes upon serum starvation in growth factor
signalling pathways amongst the NZM cell lines.
Therefore, the main difference found between normal
melanocytes and melanoma cells in culture was the
serum dependence of pathway utilisation. Although
the sensitivity of the cells harbouring different muta-
tions to inhibitors of the PI3K and MAPK pathways is
currently being investigated, unpredictable signalling
activation patterns observed in response to mutations
suggest that sensitivity to inhibitors between cell lines
harbouring the same mutation may be highly variable.
Our findings in cultured melanoma cells suggest that
the presence of activated PI3K or BRAF does induce
consistent, albeit unexpected changes in global cellu-
lar signalling. Also, it is possible that different signals
arising from mutations in other pathways can
crosstalk with the studied pathways to produce unpre-
dictable responses as we have observed. Microenvir-
onmental influences (such as paracrine signalling)
may alter the utilisation of a certain signalling path-
way over another. Although we measured phosphory-
lation status as readout for signalling pathway
activation, a more comprehensive analysis of down-
stream signalling pathways such as transcriptional
readout [44] and analysis of the proliferation of cell
lines in response to various inhibitors [20] is expected
to give a better understanding of growth factor signal-
ling pathways in melanoma. Moreover, epigenetic reg-
ulation may play a greater part in dictating pathway
activation independent of activating oncogenes or loss
of tumour suppressor mutations, which will produce
heterogeneity.
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